Literature DB >> 26084457

microRNA-340-5p Functions Downstream of Cardiotrophin-1 to Regulate Cardiac Eccentric Hypertrophy and Heart Failure via Target Gene Dystrophin.

Jian Zhou1, Jie Gao, Xiaoya Zhang, Yan Liu, Song Gu, Xitao Zhang, Xiangguang An, Jun Yan, Yue Xin, Pixiong Su.   

Abstract

Pathological cardiac hypertrophy inevitably leads to the unfavorable outcomes of heart failure (HF) or even sudden death. microRNAs are key regulation factors participating in many pathophysiological processes. Recently, we observed upregulation of microRNA-340-5p (miR-340) in failing human hearts because of dilated cardiomyopathy, but the functional consequence of miR-340 remains to be clarified.We transfected neonatal cardiomyocytes with miR-340 and found fetal gene expression including Nppa, Nppb and Myh7. We also observed eccentric hypertrophy development upon treatment which was analogous to the phenotype after cardiotrophin-1 (CT-1) stimulation. As a potent inducer of cardiac eccentric hypertrophy, treatment by IL-6 family members CT-1 and leukemia inhibitory factor (LIF) led to the elevation of miR-340. Knockdown of miR-340 using antagomir attenuated fetal gene expression and hypertrophy formation, which means miR-340 could convey the hypertrophic signal of CT-1. To demonstrate the initial factor of miR-340 activation, we constructed a volume overloaded abdominal aorta-inferior vena cava fistula rat HF model. miR-340 and CT-1 were found to be up-regulated in the left ventricle. Dystrophin (DMD), a putative target gene of miR-340 which is eccentric hypertrophy-susceptible, was decreased in this HF model upon Western blotting and immunohistochemistry tests. Luciferase assay constructed in two seed sequence of DMD gene 3'UTR showed decreased luciferase activities, and miR-340 transfected cells resulted in the degradation of DMD.miR-340 is a pro-eccentric hypertrophy miRNA, and its expression is dependent on volume overload and cytokine CT-1 activation. Cardiomyocyte structure protein DMD is a target of miR-340.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26084457     DOI: 10.1536/ihj.14-386

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  16 in total

1.  Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.

Authors:  Suriyan Ponnusamy; Ryan D Sullivan; Dahui You; Nadeem Zafar; Chuan He Yang; Thirumagal Thiyagarajan; Daniel L Johnson; Maron L Barrett; Nikki J Koehler; Mayra Star; Erin J Stephenson; Dave Bridges; Stephania A Cormier; Lawrence M Pfeffer; Ramesh Narayanan
Journal:  Hum Mol Genet       Date:  2017-07-01       Impact factor: 6.150

2.  The microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis.

Authors:  Nan-Nan Shen; Jia-Liang Wang; Yong-Ping Fu
Journal:  Front Cardiovasc Med       Date:  2022-06-15

Review 3.  Epigenetic regulation in heart failure.

Authors:  Soo Young Kim; Cyndi R Morales; Thomas G Gillette; Joseph A Hill
Journal:  Curr Opin Cardiol       Date:  2016-05       Impact factor: 2.161

4.  Mitochondria Associated MicroRNA Expression Profiling of Heart Failure.

Authors:  Xiaoxia Wang; Chun Song; Xiao Zhou; Xiaorui Han; Jun Li; Zengwu Wang; Haibao Shang; Yuli Liu; Huiqing Cao
Journal:  Biomed Res Int       Date:  2017-09-24       Impact factor: 3.411

5.  Role of miR-128 in hypertension-induced myocardial injury.

Authors:  Jie Yin; Hongyan Liu; Lei Huan; Suping Song; Liying Han; Faxin Ren; Zengtang Zhang; Zhiqiang Zang; Junye Zhang; Shu Wang
Journal:  Exp Ther Med       Date:  2017-08-04       Impact factor: 2.447

6.  Increased Interleukin-11 Levels Are Correlated with Cardiac Events in Patients with Chronic Heart Failure.

Authors:  Jing Ye; Zhen Wang; Di Ye; Yuan Wang; Menglong Wang; Qingwei Ji; Ying Huang; Ling Liu; Ying Shi; Lei Shi; Tao Zeng; Yao Xu; Jianfang Liu; Huimin Jiang; Yingzhong Lin; Jun Wan
Journal:  Mediators Inflamm       Date:  2019-01-08       Impact factor: 4.711

Review 7.  microRNAs involved in psoriasis and cardiovascular diseases.

Authors:  Sara Sileno; Sara Beji; Marco D'Agostino; Alessandra Carassiti; Guido Melillo; Alessandra Magenta
Journal:  Vasc Biol       Date:  2021-06-03

Review 8.  Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress.

Authors:  Md Sayed Ali Sheikh; Umme Salma; Baohai Zhang; Jimei Chen; Jian Zhuang; Zhu Ping
Journal:  Oxid Med Cell Longev       Date:  2016-06-09       Impact factor: 6.543

9.  Overexpression of MicroRNA-340-5p Inhibits Pulmonary Arterial Hypertension Induced by APE by Downregulating IL-1β and IL-6.

Authors:  Minghui Ou; Chuntang Zhang; Jing Chen; Shibo Zhao; Shichao Cui; Jie Tu
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-22       Impact factor: 10.183

10.  Interactions between the ERK1/2 signaling pathway and PCAF play a key role in PE‑induced cardiomyocyte hypertrophy.

Authors:  Qian Mao; Shuqi Wu; Chang Peng; Bohui Peng; Xiaomei Luo; Lixin Huang; Huanting Zhang
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.